Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term outcomes in low-risk kidney transplant recipients on tacrolimus monotherapy versus tacrolimus + mycophenolate mofetil
NL-OMON48073Phase 4Recruiting
- Sponsor
- Erasmus MC
- Start
- Aug 2019
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of tacrolimus, mycophenolate mofetil and 23-valent pneumococcal polysaccharide vaccine in kidney allograft rejection and pneumococcal disease (2 cohorts), sponsored by Erasmus MC. Primary endpoints: Long-term renal function and proteinuria, Patient survival and 3 more. Started Aug 2019; status: recruiting.
02
Drugs
tacrolimusmycophenolate mofetil23-valent pneumococcal polysaccharide vaccine
03
Conditions
kidney allograft rejectionpneumococcal disease
Beyond the preview
Go deeper on NL-OMON48073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48073.